This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2015. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, and increased slightly to over 74 percent in 2016. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
U.S. brand and generic prescription drug revenue 2005-2016
Premium statistics
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2016
Exclusive Premium Statistic
This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2015. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, and increased slightly to over 74 percent in 2016. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
| Brands | Branded Generics | Unbranded Generics | |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Brands | Branded Generics | Unbranded Generics | |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1.5m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Exclusive content
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1.5m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2015. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, and increased slightly to over 74 percent in 2016. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
Show more- Show sources information
- Show publisher information
- Release date
- May 2017
- Region
- United States
- Survey time period
- 2005 to 2016
- Supplementary notes
-
Report reflects prescription-bound products including insulins and excluding other products such as OTC.
Includes prescriptions and insulins dispensed by chain and independent pharmacies, food store pharmacies, mail service pharmacies, and long-term
care facilities. Spending figures also include sales into hospitals, clinics, and other institutional settings.
Prescription counts are not adjusted for length of therapy. 90-day and 30-day prescriptions are both counted as one prescription.
This statistic was assembled from several IMS Health/QuintilesIMS reports.
More information
- Region
- United States
- Survey time period
- 2005 to 2016
- Supplementary notes
-
Report reflects prescription-bound products including insulins and excluding other products such as OTC.
Includes prescriptions and insulins dispensed by chain and independent pharmacies, food store pharmacies, mail service pharmacies, and long-term
care facilities. Spending figures also include sales into hospitals, clinics, and other institutional settings.
Prescription counts are not adjusted for length of therapy. 90-day and 30-day prescriptions are both counted as one prescription.
This statistic was assembled from several IMS Health/QuintilesIMS reports.
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Related Studies: Available to Download in PDF or PPTX Format
All Information
in one Presentation
Generics and biosimilars
- 86 page/s
- English
- pptx
- Detailed references
Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.
Other Reports & Dossiers
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation
Statistics on "Generics and biosimilars"
- Global overview
The most important statistics
- Revenue of the worldwide pharmaceutical market from 2001 to 2017 (in billion U.S. dollars)Pharmaceutical market: worldwide revenue 2001-2017
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)Total worldwide generic prescription drug revenue 2010-2024
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Top companies
The most important statistics
- Top generics manufacturers based on revenue in 2016 (in billion U.S. dollars)*Revenues of leading global generics manufacturers 2016
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)Teva Pharmaceutical Industries' generic revenues by region 2016-2018
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)Novartis revenue 2014-2018 by segment
- Pfizer's revenue in 2014 and 2017, by segment (in million U.S. dollars)*Pfizer's revenue by segment 2014-2017
- U.S. market
The most important statistics
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2016 (in billion U.S. dollars)*Brand and generic prescription medication revenue in the U.S. 2006-2016
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2016U.S. brand and generic prescription drug revenue 2005-2016
- Change in branded and generic medication spending in the United States from 2013 to 2017 (in billion U.S. dollars)*Spending change on branded and generic medicines in the U.S. 2013-2017
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*Unbranded generics revenue top corporations in U.S. 2016-2017
- Top companies based on unbranded generics U.S. market share during 2016-2017*Unbranded generics market share top corporations in U.S. 2016-2017
- Top 20 U.S. pharma products by dispensed prescriptions in 2016 (in millions)Top U.S. pharma products by prescriptions 2016
- Patent expiration
The most important statistics
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)Projected sales at risk due to patent expiry 2009-2022
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018Top pharma companies by sales loss due to patent loss until 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*Top branded biologic drugs in the U.S. that will go generic by 2028
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)Comparison of pre-expiry and generic price for drugs U.S. 2015
- Savings
The most important statistics
- Savings through generic drug usage in the United States from 2008 to 2017 (in billion U.S. dollars)Savings through generic drug usage in the U.S. 2008-2017
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)Total savings of top generic drugs in U.S. 2017
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*Saving of U.S. costs through generic pharmaceuticals by therapy 2017
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)Savings through generic drug usage in the U.S., by age group 2017
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)Savings through generic drug usage in the U.S., by payer 2017
- Percentage of savings through generic drug usage in the United States in 2017, by payerPercentage savings through generic drug usage in the U.S. by payer 2017
- Percentage of savings through generic drug usage in the United States in 2017, by age groupSavings through generic drug usage in the U.S., by age group share 2017
- Biosimilars
The most important statistics
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Number of biosimilars in development worldwide as of October 2017, by country Country-wise biosimilar pipelines number in development worldwide 2017
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)Reduction in U.S. direct spending on originator biologics as of 2018
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Example of physician office payment for biosimilars in Medicare Part B as of 2018 (in U.S. dollars)*Physician office payment for biosimilars in Medicare Part B in 2018
Popular Related Keywords
- brands
- drug
- revenue distribution
- generic drug
- sales
- Show more
- prescription
- drugs
- health
- health service
- branded products
- Pharmaceutical companies
- consumer health care
- healthcare
- generics
- consumer health products
- pharmaceutical products
- pharmaceutical regulations
- brand popularity
- pharmaceutical industry
- generics market
- generics manufacturers
- health sector
- pharmaceutical manufacturers
- retail brand share
- pharmaceutical data
- health market
- pharmaceutical business
- pharmaceutical market
- drug prescription rates
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- U.S. spending on biosimilars by type 2014
- U.S. spending on specialty medicine by type 2012-2016
- U.S. spending growth on new brand specialty medicine by type 2014-2015
- U.S. spending on multiple sclerosis medicine by type 2010-2014
- Spending on dispensed total vs. generic prescriptions in the U.S. 2017
- Number of ANDA approvals in U.S. 2015-2017, by type
- U.S. total vs. generic dispensed prescription numbers 2017, by formulation
- Generic share of dispensed prescriptions by formulation U.S. 2012 vs. 2017
- Average number of approved ANDAs per month in U.S. 2009-2017
- Medicare savings through generic drug usage in the U.S. by state 2015
- Medicaid program savings through generic drug usage by U.S. state 2015
- Average number of ANDAs received per month in U.S. 2009-2017
- Generic drug savings forecast for Canada 2015-2017
- Share of drug dispensing costs in select public drug plans Canada 2011-2017
- Number of pharmaceuticals on China's national reimbursement drug list
- Multidrug-resistant TB cases enrolled for treatment by world region 2009-2012
- Italy: prevalence of generic diuretic use 2006-2016
- Volume share of the generic pharmaceuticals market in France 2004-2015
- Drug shortages of individual drugs experienced by hospitals in U.S.
- Leading hair growth products in U.S. 2018
Studies
- Prescribed Drug Spending in Canada, 2018
- CDER 2018 New Drug Therapy Approvals
- Drug Use Among Seniors in Canada, 2016
- Prescribed Drug Spending in Canada, 2017
- CDER 2017 New Drug Therapy Approvals
- Compass Rx - Annual Public Drug Plan Expenditure Report 2015/16
- CDER New Drugs Program: 2018 Update
- Meds Entry Watch 2016
- Compass Rx - Annual Public Drug Plan Expenditure Report 2012/13
- Showdown over drug pricing
- Prescribed Drug Spending in Canada, 2013
- Prescribed Drug Spending in Canada, 2016
- Patented Medicine Prices Review Board - Annual Report 2017
- Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans: 2006 to 2015
- Compass Rx - Annual Public Drug Plan Expenditure Report 2013/14
Statistics on the topic
Free statistics
- Change in branded and generic medication spending in the United States from 2013 to 2017 (in billion U.S. dollars)*
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)
- Percentage of savings through generic drug usage in the United States in 2017, by payer
- Number of biosimilars in development worldwide as of October 2017, by country
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*
- Example of physician office payment for biosimilars in Medicare Part B as of 2018 (in U.S. dollars)*
- Spending growth on new brand specialty medicines in the United States in 2014 and 2015, by type (in billion U.S. dollars)
- Spending on dispensed total vs. generics prescriptions in the U.S. in 2017, by formulation (in billion U.S. dollars)
- Number of abbreviated new drug applications (ANDAs) approvals in the U.S. from 2015 to 2017, by type of approval
- Number of dispensed total vs. generics prescriptions in the U.S. in 2017, by formulation (in millions)
- Dispensing costs as share of total Rx drug costs in select public drug plans in Canada from 2011/2012 to 2016/2017
- Enrollment in multidrug-resistance tuberculosis treatment from 2009 to 2012, by world region
Premium Statistics
- Revenue of the worldwide pharmaceutical market from 2001 to 2017 (in billion U.S. dollars)
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*
- Top generics manufacturers based on revenue in 2016 (in billion U.S. dollars)*
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)
- Pfizer's revenue in 2014 and 2017, by segment (in million U.S. dollars)*
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2016 (in billion U.S. dollars)*
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2016
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*
- Top companies based on unbranded generics U.S. market share during 2016-2017*
- Top 20 U.S. pharma products by dispensed prescriptions in 2016 (in millions)
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018
- Savings through generic drug usage in the United States from 2008 to 2017 (in billion U.S. dollars)
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)
- Percentage of savings through generic drug usage in the United States in 2017, by age group
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)
- Expenditure on biosimilars in the United States in 2014, by type (in billion U.S. dollars)*
- Expenditure on specialty medicines in the United States from 2012 to 2016, by type (in billion U.S. dollars)
- Expenditure on multiple sclerosis medicines in the United States from 2010 to 2014, by type (in billion U.S. dollars)
- Percentage of U.S. dispensed prescriptions that were generics in 2012 and 2017, by formulation
- Average number of approved abbreviated new drug applications (ANDAs) per month in the U.S. from 2009 to 2017
- Savings through generic drug usage in Medicare during 2015, by state (in million U.S. dollars)*
- Savings through generic drug usage in Medicaid during 2015, by state (in million U.S. dollars)
- Average number of abbreviated new drug applications (ANDAs) received per month in the U.S. from 2009 to 2017
- Forecast of generic drug savings in Canada from 2015 to 2017 (in million Canadian dollars)
- Number of pharmaceuticals on China's national reimbursement drug list in 2009, by type and list allocation*
- Share of individuals taking generic diuretics* in Italy from 2006 to 2016
- Share of the generic pharmaceuticals market volume in France from 2004 to 2015
- Percent of hospitals experiencing a drug shortage in the last six months by treatment category
- Sales of the leading hair growth product brands in the United States in 2018 (in thousand U.S. dollars)
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Save statistic in .XLS format
You can only download this statistic as a Premium user.
Save statistic in .PNG format
You can only download this statistic as a Premium user.
Save statistic in .PDF format
You can only download this statistic as a Premium user.
Show source references
As a Premium user you get access to the detailed source references and background information about this statistic.
Show details about this statistic
As a Premium user you get access to background information and details about the release of this statistic.
Bookmark statistics
As soon as this statistic is updated, you will immediately be notified via e-mail.
Change statistics options
You need at least a Premium Account to use this feature.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
News
News
Latest News
Updated
The Italian pharmaceutical market
The Italian pharmaceutical market is among the fastest growing ones worldwide. This dossier provides data on the trends of the market, with special focus on pharmaceutical segments.
Updated
Update & expansion: Country Reports
To our 150 Reports we added:
- Global Consumer Survey content
- Operational risk index by Fitch
- And more …
New
New Dossier: Plastic industry worldwide
The global plastics industry is growing by approximately three percent every year. This dossier provides information about the global plastics industry in general as well as chapters on the major types of plastic, and recycling rates.
Updated
New Digital Market Outlook Reports for 2019
Updates on eCommerce, Digital Media, eTravel, eServices and more
- Market figures for 2018 to 2023
- Company and startup profiles
- User demographics
New
New Dossier: United States coal mining industry
U.S. coal production has steadily declined in the past decade, but has been in the news in recent years due to President Trump's desire to revitalize the industry. This document provides an overview of the key figures, leading companies, and the employment trends in the U.S. coal mining industry.
New
Global Consumer Survey offers PowerPoint export
This new export feature offers
- Structured graphical representation of the data
- Tailored target group analysis
- Option for further processing
New
New Dossier: E-commerce in Poland
The Polish e-commerce market is one of the fastest developing e-commerce markets in Europe. The latest data for Poland is presented in this dossier.
New
New Dossier: Plastic waste in the U.S.
Plastic waste is an issue of global concern. Since China banned the import of recycled plastic, the U.S. has had to make adjustments to its management of plastic waste. This dossier provides an overview of plastic waste in the U.S.
New
New Dossier: Hedge funds
This dossier provides an overview of hedge funds worldwide. Global hedge fund assets, performance, investors, and other topics are highlighted.
New
New exclusive OOH advertising data by OAAA
The Outdoor Advertising Association of America covers amongst others
- Number of billboards
- Outdoor advertising revenue
- Number of out-of-home displays
New
What happens after a no-deal Brexit?
Find data, perceptions & more about
- Economic consequences
- Impact on the labor market
- A second referendum
New
ecommerceDB.com: Ranking update – Spain
Understand the recent developments in the Spanish eCommerce market!
- URL-related revenues
- Relevant online store KPIs
- eCommerce-related contacts
New
Insights into the European banking sector
- Extended statistical dossier
- Insights, explanations & interpretations
- Challenges of the digital future
New
Dossier: Latin American online shopping events
eCommerce is rapidly becoming a part of the Latin American shopping culture. The dossier includes data on
- Regional online shopping events
- Events by country
Updated
Updated Brexit analysis in UK Industry Reports
The outline of potential impacts of Brexit on UK industries has been updated in the UK Industry Reports.
New
New Dossier: Digital Marketing in Italy
Italian enterprises invest significantly in digital marketing. Find out about
- Relevant aspects & KPIs
- New trends
- Different strategies
New
What is football all about, anyway?
Statista European Football Benchmark
- The big 5 European leagues
- All about the clubs & fans
- Sponsors & how they fit in
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.